WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Ekta A. Andriyas, Neha Pant, Neetu Kushwaha, Deepak Sharma, Arun Kumar Saxena, Munzali Hamisu Umar and Imran Hussain*

ABSTRACT

The malignant tumor known as acute myeloid leukemia (AML) affects hemopoietic stem cells and progenitor cells. It is typified by an irregular proliferation of primitive cells in the bone marrow and peripheral circulation. Anaemia, bleeding, infection, and organ infiltration are among the clinical signs and symptoms of acute myeloid leukemia. An increased frequency of AML has been seen over time, men have been more likely than women to have AML, and the disease's incidence has been rising. Currently, the most significant predictors of AML outcomes are still cytogenetic and molecular abnormalities. These parameters are tightly linked to clinical characteristics such as age, white blood cell count and morphology, treatment response, recurrence rate, and overall survival (OS). The World Health Organisation (WHO) and European Leukaemia Net (ELN) have developed illness prognostic classification on the strong basis of this. Currently, less than 50% of adult AML patients will survive for five years; this percentage is much lower for older patients. According to statistics, patients over 65 have a median overall survival of less than a year. This article outlines the molecular indicators associated with AML and their clinical significance for early diagnosis and prognosis. Prognostic indicators can gauge the severity of a patient's condition and forecast their long-term results, while predictive markers facilitate the tracking of therapy response and recurrence.

[Full Text Article] [Download Certificate]